Lv11
8 积分 2026-03-19 加入
PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial
7小时前
已完结
Hodgkin Lenfoma
8小时前
已完结
P3.18.78 A Prospective Study of Lurbinectedin Plusivonescimab Assecond-Line Treatment for Extensive-Stage Small Cell Lung Cancer
20天前
已关闭
Paclitaxel plus bevacizumab in patients with chemoresistant relapsed small cell lung cancer as salvage treatment: A phase II multicenter study of the Hellenic Oncology Research Group
20天前
已完结
Anlotinib Combined With Sintilimab as Third-line Treatment or Beyond in Patients With Small Cell Lung Cancer
21天前
已关闭
69P Combining sintilimab with anlotinib as second-line or later therapy in patients with extensive-disease small cell lung cancer: A prospective, single-arm, phase II trial
21天前
已完结
The efficacy and safety of anlotinib for subsequent line treatment of small cell lung cancer: a systematic review and meta-analysis
21天前
已完结
Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial
22天前
已完结
Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial
22天前
已完结
皖公网安备34019202002308
